Sugi Predict

Sugi Predict / Compounds / SCHEMBL4611345

SCHEMBL4611345

SCHEMBL4611345

CC(C)C(CS(=O)(=O)Cl)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ LMNA P02545 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ NOS1 P29475 2/20 0.31
▸ NOS3 P29474 1/20 0.31
▸ NOS2 P35228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25889335 0.75 CA1 (0.39) CA12CA14CA1CA2CA7
SCHEMBL15406549 0.75 CA1 (0.39) CA12CA14CA1CA2CA7
SCHEMBL29053947 0.75 CA1 (0.39) CA12CA14CA1CA2CA7
SCHEMBL14220668 0.73 CA1 (0.38) CA12CA14CA1CA2CA7
SCHEMBL25687930 0.73 CA1 (0.42) CA1CA2CA7KMT2ACYP2D6
SCHEMBL4610817 0.73 CA1 (0.38) CA12CA14CA1CA2CA7
SCHEMBL6036741 0.72 SLC1A3 (0.43) —
SCHEMBL14001805 0.72 TDP1 (0.39) CA12CA1CA2CA7KMT2A
SCHEMBL5613372 0.71 CTSK (0.34) CA1CA2CA7LMNAKMT2A
SCHEMBL27535928 0.70 CA1 (0.36) CA12CA14CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 — — EP disclosed
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-12-07 — — US disclosed
EP-1648868-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R&D LTD (GB) 2006-11-15 — — EP disclosed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 — — US disclosed
EP-1648868-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-26 — — EP disclosed
EP-1641771-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-05 — — EP disclosed
US-6933306-B2 Hydroxamic and carboxylic acid derivatives DARWIN DISCOVERY LTD. (GB) 2005-08-23 — — US disclosed
US-20040266764-A1 Hydroxamic acid derivatives HANNAH DUNCAN ROBERT 2004-12-30 — — US disclosed
WO-2004113298-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 — — WO disclosed
WO-2004113312-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 — — WO disclosed
US-6506773-B2 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration DARWIN DISCOVERY LTD. (GB) 2003-01-14 — — US disclosed
US-6469020-B2 AS INHIBITORS OF MATRIX METALLOPROTEINASE, FOR THERAPY OF DISEASES SUCH AS DEGENERATIVE DISEASES AND CERTAIN CANCERS DARWIN DISCOVERY, LTD. (GB) 2002-10-22 — — US disclosed
US-20020037900-A1 Hydroxamic acid derivatives DARWIN DISCOVERY LIMITED (GB) 2002-03-28 — — US disclosed
US-20020022635-A1 Hydroxamic and carboxylic acid derivatives DARWIN DISCOVERY LIMITED (GB) 2002-02-21 — — US disclosed
EP-1177174-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES Darwin Discovery Limited (GB) 2002-02-06 — — EP disclosed
US-20020013333-A1 Hydroxamic and carboxylic acid derivatives DARWIN DISCOVERY LIMITED (GB) 2002-01-31 — — US disclosed
WO-2001087870-A1 HYDROXAMIC ACID DERIVATIVES DARWIN DISCOVERY LIMITED (GB) 2001-11-22 — — WO disclosed
WO-2001087844-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY DARWIN DISCOVERY LIMITED (GB) 2001-11-22 — — WO disclosed
WO-2001087883-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY DARWIN DISCOVERY LIMITED (GB) 2001-11-22 — — WO disclosed
WO-2000069822-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES DARWIN DISCOVERY LIMITED (GB) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013333-A1 Hydroxamic and carboxylic acid derivatives HCAR2, HCAR1, CBR1 CA12 856/4885CA14 1116/4885CA1 759/4885
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD2, CD22, NEU3 CA12 183/4885CA14 149/4885CA1 254/4885
US-20020022635-A1 Hydroxamic and carboxylic acid derivatives HCAR1, HCAR2, HCAR3 CA12 2263/4885CA14 1855/4885CA1 961/4885
US-20020037900-A1 Hydroxamic acid derivatives ADAM17, ADAM10, ADAM33 CA12 327/4885CA14 446/4885CA1 113/4885
US-20040266764-A1 Hydroxamic acid derivatives ADAM17, ADAM10, ADAM33 CA12 327/4885CA14 446/4885CA1 113/4885
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD22, CD2, DPP3 CA12 168/4885CA14 192/4885CA1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.